TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTTECHNOLOGYMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTER
Search

LATEST NEWS

Nektar Is the One S&P 500 Company Without a Woman Director
INVESTING

Nektar Shares Drop After Double Downgrade to Sell at Goldman Sachs

PRESS RELEASES

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

PRESS RELEASES

Puma Biotechnology Presents Interim Results From The Phase II SUMMIT Trial Of Neratinib For EGFR Exon 18-Mutated, Metastatic Non-Small Cell Lung Cancer At WCLC 2020

PRESS RELEASES

Puma Biotechnology To Present At The B. Riley Oncology Investor Conference

PRESS RELEASES

Puma Biotechnology Presents Interim Results From The Biliary Tract Cancers Cohort Of The Phase II SUMMIT "Basket" Trial Of Neratinib At ASCO GI

PRESS RELEASES

Puma Biotechnology To Present At The J.P. Morgan Healthcare Conference

PRESS RELEASES

Puma Biotechnology To Present At The H.C. Wainwright VIRTUAL BioConnect Conference

PRESS RELEASES

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

PRESS RELEASES

Puma Biotechnology: NALA Spotlight Poster At SABCS 2020.

PRESS RELEASES

Puma Biotechnology: ExteNET Spotlight Poster At SABCS 2020

PRESS RELEASES

Puma Biotechnology - SUMMIT Spotlight Poster At SABCS 2020

PRESS RELEASES

Puma Biotechnology, Inc. Prevails Before European Patent Office Board Of Appeals In Decision Upholding European Patent (EP 1848414) As Granted

PRESS RELEASES

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

PRESS RELEASES

Puma Biotechnology Announces Interim Results From The Phase II SUMMIT Trial Of Neratinib For EGFR Exon 18 Mutated, Metastatic Non-Small Cell Lung Cancer

PRESS RELEASES

Puma Biotechnology To Present At The Credit Suisse 29th Annual Virtual Healthcare Conference

PRESS RELEASES

Puma Biotechnology To Host Conference Call To Discuss Third Quarter Financial Results

PRESS RELEASES

Puma Biotechnology Announces Publication Of Overall Survival Results From Phase III ExteNET Trial Evaluating Neratinib In HER2-Positive, Hormone Receptor-Positive, Early Stage Breast Cancer

PRESS RELEASES

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

PRESS RELEASES

Puma Biotechnology To Present At The H.C. Wainwright 22nd Annual Global Investment Conference

PRESS RELEASES

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

PRESS RELEASES

Puma Biotechnology Announces Publication Of Interim Results Of Phase II CONTROL Trial In Annals Of Oncology

PRESS RELEASES

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

PRESS RELEASES

Puma Biotechnology Announces Publication Of Results From Phase II SUMMIT Trial Evaluating Neratinib In HER2-Mutant, Metastatic Cervical Cancers

PRESS RELEASES

Puma Biotechnology To Host Conference Call To Discuss Second Quarter Financial Results

PRESS RELEASES

Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval In Malaysia For NERLYNX® (neratinib) For Extended Adjuvant Treatment Of Early Stage HER2-Positive Breast Cancer